Jacob Gottlieb began his career as a founding member at Balyasny Asset Management (BAM), where he was in charge of global heath care for 2 years. From there, he founded Visium Asset Management in 2005. Within 11 years, Visium grew to a hedge fund worth over $8 billion and employed over 200 people. After allegations of insider trading, of which the two that were accused were acquitted, Jacob was the only key executive to remain. From there, he founded Altium Capital to empower healthcare enterprises that would grow companies that progress purposeful health and medical treatments. His first investment was a 5.6% stake in Oramed who made breakthroughs with an oral insulin capsule. Until this innovation, using a syringe to inject insulin was the only option diabetics had. His second investment was a 9.8% stake in Sellas, a companies that working on immunotherapies to combat signals of cancerous cells. Another one of Gottlieb’s investments was Oragenics. This company, co-founded by 2 physicians in 1996, fouces on Replacement Therapy; which is the practice of eliminating harmful bacteria and replacing them with beneficial bacteria. Also in his portfolio is Amarin; a Dublin, Ireland company that focuses on medicines for heart health. Amarin was credited for for incenting Vascepa, a prescription grade omega-3 fatty acid, which was approved by the FDA in 2012This, along with investments in Amarin and Oragenics landed him sharing an office with Stuart Weisbrod, a long time colleague and fellow investment celebrity.
In addition to his notoriety as an investment professional, while building his newest venture, Gottlieb is extremely involved in charity work. He credits his success to educations, so he invests in supporting local New York City charities that encourage educational growth for children. He has been a long time fundraiser, raising millions for these local non profit charities.